Study on the Role of Vitamin D in Systemic Lupus Erythematosus

Authors

  • Jiadian Wang The First Clinical School of Hainan Medical University
  • Muzi Cui The Second Clinical College of Hainan Medical University
  • Siyi Wang The Clinical College of Hainan Medical University
  • Xiao Xue The First Clinical School of Hainan Medical University
  • Kerong Ren The School of International Nursing, Hainan Medical University
  • ZhiLu Li The First Clinical School of Hainan Medical University
  • Saijia Li The First Clinical School of Hainan Medical University
  • Pingping Yan The Clinical Skills Center of Hainan Medical University

DOI:

https://doi.org/10.30564/jams.v4i1.2728

Abstract

Vitamin D is a hormone precursor with multiple biological effects. It binds to vitamin D receptors on target cells. It is an important participant in the metabolism of calcium and phosphorus in vivo. It is closely related to cell cycle, cell proliferation, differentiation, apoptosis, signal transduction and immune regulation. Its role in the treatment of infection, tumor and even immune diseases has been gradually recognized and studied. Patients with systemic lupus erythematosus generally have decreased levels of active vitamin D, and low levels of vitamin D are associated with disease occurrence, disease activity and complications. In the past ten years, a large number of studies have been carried out on it globally to explore the role of vitamin D in the occurrence and development of systemic lupus erythematosus. This paper summarizes its recent research progress.

Keywords:

Vitamin D; Systemic lupus erythematosus; Action research

References

[1] Kong L J. Gene, environmental factors and gene-environment interaction of systemic lupus erythematosus [D]. Shanghai: Fudan University, 2018:13-53.

[2] Müller K, Kriegbaum NJ, Baslund B, et al. Vitamin D3 metabo- lism in patients with rheumatic diseases: Low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythema- tosus[J].Clin Rheumatol, 1995, 14 (4): 397-400.

[3] Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: A comparison of worldwide disease bur- den[J]. Lupus, 2016,15(5): 308-318.

[4] IruretagoyenaM, Hirigoyen D, NavesＲ, et al. Immune re- sponse modulation by vitamin D: role in systemiclupus ery- thematosus[J]. Front Immunol, 2015,12(6):513-515.

[5] Christakos S, Dhawan P, Verstuyf A, et al. Vitamin D: Metabo-lism, molecular mechanism of action, and pleiotropic effects[J]. Physiol Rev, 2016,96 (1):365-408.

[6] SuainiNH, ZhangY, VuillerminPJ, et al. Immune modulation by Vitamin D and its relevance to food allergy. Nutrients, 2015,7(14):6088- 6108.

[7] Herrmann M, Farrell CL, Pusceddu I, et al. Assessment of vi- tamin D statusa changing landscape[J]. Clin Chem Lab Med, 2017,55(21):3 - 26.

[8] Wang Yonghui, Song Weiqiang, Liu Miao, et al. Progress in the study of the structure-activity relationship of active vitamin D3[J]. drugs Huaxi Pharmaceutical Journal,2014, 29 (4): 455-459.

[9] Gao CC, Liu SY, Wu ZZ, et al. Severe vitamin D deficiency increases the risk for moderate to severe disease activity in Chi-nese patients with SLE[J]. Lupus, 2016, 25 (11):1224-1229.

[10] Chen S, Sims GP, Chen XX, et al. Modulatory effects of 1, 25-dihydroxyvitamin D3 on human B cell differentiation[J]. J Immunol, 2007, 179 (3): 1634-1647.

[11] Okpechi IG, Ameh OI. Lupus nephritis: An approach to diagnosis and treatment in South Africa[J]. S Afr Med J, 2015, 105 (12): 1071-1074.

[12] Mao S, Huang S. Association between vitamin D receptor gene BsmI, FokI, ApaI and TaqI polymorphisms and the risk of syste- mic lupus erythematosus: A meta-analysis[J]. Rheumatol Int, 2014, 34 (3): 381-388.

[13] Piantoni S, Andreoli L, Scarsi M, et al. Phenotype modifications of T-cells and their shift toward a Th2 response in patients with sys-temic lupus erythematosus supplemented with different monthly regimens of vitamin D[J]. Lupus, 2015, 24 (4 /5): 490-498.

[14] Hu W, Niu G, Lin Y, et al. Impact of the polymorphism in vita-min D receptor gene BsmI and the risk of systemic lupus erythe-matosus: An updated meta-analysis[J]. Clin Rheumatol, 2016, 35 (4): 927-934.

[15] Luo XY, Wu LJ, Chen L, et al. Study on the correlation between vitamin D receptor Apa Ⅰ and Bsm Ⅰ locus gene polymorphism and systemic lupus erythematosus[J]. CHINESE JOURNAL OF INTERNAL MEDICINE ,2012, 51 (2): 131-135.

[16] Li L, Yang B, Wang L. Impact of the polymorphism in vitamin D receptor gene BsmI and the risk of systemic lupus erythema- tosus[J]. Clin Rheumatol, 2016, 35 (4): 1121.

[17] Ruiz-Irastorza G, García M, Espinosa G, et al. Patterns of drugtherapy in newly diagnosed Spanish patients with systemic lupus erythematosus[J]. Clin Exp Rheumatol, 2016, 34 (3): 466-472.

[18] Squance ML, Reeves GE, Tran HA. Vitamin D levels are asso- ciated with expression of SLE, but not flare frequency[J]. Int J Rheumatol, 2017, 2014: 362834.

[19] Schoindre Y, Jallouli M, Tanguy ML, et al. Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up[J].Lupus Sci Med, 2014, 1 (1): 15-27.

[20] Sahebari M, Nabavi N, Salehi M. Correlation between serum 25 (OH) D values and lupus disease activity: An original article and a systematic review with meta-analysis focusing on serum VitD confounders[J]. Lupus, 2017,23 (11): 1164-1177.

[21] McGhie TK, Deceulaer K, Walters CA, et al. Vitamin D levels inJamaican patients with systemic lupus erythematosus[J]. Lupus, 2015, 23 (10): 1092-1096.

[22] AlSaleem A, AlE’ ed A, AlSaghier A, et al. Vitamin D status in children with systemic lupus erythematosus and its association with clinical and laboratory parameters[J] Clin Rheumatol, 2015, 34 (1): 81-84.

[23] Stagi S, Cavalli L, Bertini F, et al. Vitamin D levels in children, adolescents, and young adults with juvenile-onset systemic lupus erythematosus: A cross-sectional study[J]. Lupus, 2014, 23 (10):1059-1065.

[24] de Souza VA, Fernandes NM. Association of hypovitaminosis D with systemic lupus erythematosus and inflam- mation[J].J Bras Nefrol, 2014, 36 (4): 430-436.

[25] Handono K, Marisa D, Kalim H. Association between the low lev- els of vitamin D and Treg function in systemic lupus erythemato- sus patients[J]. Acta Med Indones, 2016, 45 (1): 26-31.

[26] Lavi Arab F, Rastin M, Faraji F, et al. Assessment of 1, 25-dihydroxyvitamin D3 effects on Treg cells in a mouse model of sys-temic lupus erythematosu[J]. Immunopharmacol Immunotoxicol, 2015, 37 (1): 12-18.

[27] Iruretagoyena M, Hirigoyen D, Naves R, et al. Immune response modulation by vitamin D: Role in systemic lupus erythema-tosus[J]. Front Immunol, 2015, 6: 513.

[28] Schneider L, Colar da , Silva AC, Werres Junior LC, et al. Vita- min D levels and cytokine profiles in patients with systemic lupus erythematosus[J]. Lupus, 2015, 24 (11): 1191-1197.

[29] Zhao M, Duan XH, Wu zz, et al. Severe vita-min D deficiency affects the expression of autophagy related genes in PBMCs andT-cell subsets in active systemic lupus erythema-tosus[J]. Am J Clin Exp Immunol, 2017, 6 (4): 43-51.

[30] Mandal M, Tripathy R, Panda AK, et al. Vitamin D levels inIndian systemic lupus erythematosus patients: Association with disease activity index and interferon alph[J]. Arthritis Res Ther, 2017, 16 (1): R49.

[31] Aranow C, Kamen DL, Dall’ Era M, et al. Randomized, double-blind, placebo-controlled trial of the effect of vitamin D3 on theinterferon signature in patients with systemic lupus erythema- tosus[J]. Arthritis Rheumatol, 2015, 67 (7): 1848-1857.

[32] Hoffecker BM, Raffield LM, Kamen DL, et al. Systemic lupus ery-thematosus and vitamin D deficiency are associated with shorter telomere length among African Americans: A case-control study[J]. PLoS One, 2015, 8 (5):718-725.

[33] Sangüesa Gómez C, Flores Robles BJ, Andréu JL. Bone health, vitamin D and lupus[J]. Reumatol Clin, 2015, 11 (4): 232-236.

[34] Carli L, Tani C, Spera V, et al. Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythema-tosus[J]. Lupus Sci Med, 2016, 3 (1):98-101.

[35] Bogaczewicz J, Karczmarewicz E, Pludowski P, et al. Requirement for vitamin D supplementation in patients using photoprotection:Variations in vitamin D levels and bone formation markers[J]. Int J Dermatol, 2016, 55 (4): 176-183.

[36] Edens C, Robinson AB. Systemic lupus erythematosus, bone health, and osteoporosis[J]. Curr Opin Endocrinol Diabetes Obes, 2015, 22 (6): 422-431.

[37] Tang Y, Xie H, Chen J, et al. Activated NF-κB in bone marrow mesenchymal stem cells from systemic lupus erythematosus patients inhibits osteogenic differentiation through downregulating Smad signaling[J]. Stem Cells Dev, 2017, 22 (4): 668-678.

[38] Sabio JM, Vargas-Hitos JA, Martinez-Bordonado J, et al. Associa-tion between low 25-hydroxyvitamin D, insulin resistance and arterial stiffness in nondiabetic women with systemic lupus erythe- matosus[J]. Lupus, 2015, 24 (2): 155-163.

[39] Reynolds JA, Haque S, Williamson K, et al. Vitamin D improves endothelial dysfunction and restores myeloid angiogenic cell func- tion via reduced CXCL-10 expression in systemic lupus erythema- tosus[J]. Sci Rep, 2016, 6: 22341.

[40] Reynolds J, Ray D, Alexander MY, et al. Role of vitamin D in endothelial function and endothelial repair in clinically stable sys- temic lupus erythematosus[J]. Lancet, 2015, 385 (1): 83-85.

[41] Kamen DL, Oates JC. A pilot study to determine if vitamin D repletion improves endothelial function in lupus patients[J]. Am J Med Sci, 2015, 350 (4): 302-307.

[42] Tay SH, Ho CS, Ho RC, et al. 25-Hydroxyvitamin D3 deficiency independently predicts cognitive limpairment in patients with syste-mic upus erythematosus[J]. PLoS One, 2015, 10 (12): 144-149.

[43] Gholamrezaei A, Bonakdar ZS, Mirbagher L, et al. Sleep disorders in systemic lupus erythematosus. Does vitamin D play a role [J]. Lupus, 2017,23 (10): 1054-1058.

[44] Petri M, Bello KJ, Fang H, et al. Vitamin D in systemic lupus ery- thematosus: Modest association with disease activity and the urine protein-to-creatinine ratio[J]. Arthritis Rheum, 2013, 65 (7):1865-1871.

[45] García-Carrasco M, Mendoza-Pinto C, Etchegaray-Morales I, et al. Vitamin D insufficiency and deficiency in mexican patients with systemic lupus erythematosus: Prevalence and relationship with disease activity[J]. Reumatol Clin, 2017, 13 (2): 97-101.

[46] Lima GL, Paupitz J, Aikawa NE, et al. Vitamin D supplementationin adolescents and young adults with juvenile systemic lupus ery-thematosus for improvement in disease activity and fatigue scores: A randomized, double-blind, placebo-controlled trial[J]. Arthritis Care Res (Hoboken), 2016, 68 (1): 91-98.

[47] Andreoli L, Dall’Ara F, Piantoni S, et al. A 24-month prospective study on the efficacy and safety of two different monthly regimens of vitamin D supplementation in pre-menopausal women with sys- temic lupus erythematosus[J]. Lupus, 2015, 24 (4 /5): 499-506.

[48] Banica LM, Besliu AN, Pistol GC, et al. Dysregulation of anergy-related factors involved in regulatory T cells defects in systemic lupus erythematosus patients: Rapamycin and vitamin D efficacy in restoring regulatory T cells[J]. Int J Rheum Dis, 2016, 19 (12): 1294-1303.

[49] Handono K, Sidarta YO, Pradana BA, et al. Vitamin D preventsendothelial damage induced by increased neutrophil extracellular Traps formation in patients with systemic lupus erythema- tosus[J]. Acta Med Indones, 2014, 46 (3): 189-198.

[50] Wahono CS, Rusmini H, Soelistyoningsih D, et al. Effects of 1, 25 (OH) 2 D3 in immune response regulation of systemic lupus erithematosus (SLE) patient with hypovitamin D[J]. Int J Clin Exp Med, 2014, 7 (1): 22-31.

[51] Wu HJ, Lo Y, Luk D, et al. Alternatively activated dendritic cells derived from systemic lupus erythematosus patients have tolero-genic phenotype and function[J]. Clin Immunol, 2015, 156 (1):43-57.

Downloads

Issue

Vol. 4 , Iss. 1 (January 2021)

Article Type

Articles

License

Copyright and Licensing

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

Journal of Advances in Medicine Science publishes accepted manuscripts under Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). Authors who submit their papers for publication by Journal of Advances in Medicine Science agree to have the CC BY-NC 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for non-commercial use. As long as you follow the license terms and original source is properly cited, anyone may copy, redistribute the material in any medium or format, remix, transform, and build upon the material.

License Policy for Reuse of Third-Party Materials

If a manuscript submitted to the journal contains the materials which are held in copyright by a third-party, authors are responsible for obtaining permissions from the copyright holder to reuse or republish any previously published figures, illustrations, charts, tables, photographs, and text excerpts, etc. When submitting a manuscript, official written proof of permission must be provided and clearly stated in the cover letter.
The editorial office of the journal has the right to reject/retract articles that reuse third-party materials without permission.

Journal Policies on Data Sharing

We encourage authors to share articles published in our journal to other data platforms, but only if it is noted that it has been published in this journal.